The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Open accessAbstract
Antisense-mediated modulation of splicing is one of the few fields where antisense oligonucleotides (AONs) have been able to live up to their expectations. In this approach, AONs are implemented to restore cryptic splicing, to change levels of alternatively spliced genes, or, in case of Duchenne muscular dystrophy (DMD), to skip an exon in order to restore a disrupted reading frame. The latter allows the generation of internally deleted, but largely functional, dystrophin proteins and would convert a severe DMD into a milder Becker muscular dystrophy phenotype. In fact, exon skipping is currently one of the most promising therapeutic tools for DMD, and a successful first-in-man trial has recently been completed. In this review the applicability of exon skipping for DMD and other diseases is described. For DMD AONs have been designed for numerous exons, which has given us insight into their mode of action, splicing in general, and splicing of the DMD gene in particular. In addition, retrospective analysis resulted in guidelines for AON design for DMD and most likely other genes as well. This knowledge allows us to optimize therapeutic exon skipping, but also opens up a range of other applications for the exon skipping approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Listening to silence and understanding nonsense: exonic mutations that affect splicing
Cartegni, L., Chew, S. L., & Krainer, A. R. (2002) · Nature Reviews Genetics · doi:10.1038/nrg775 · Cited by 2,209
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
ESEfinder: a web resource to identify exonic splicing enhancers
Cartegni, L. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg616 · Cited by 1,603
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988) · Cell · doi:10.1016/0092-8674(88)90383-2 · Cited by 1,538
Krawczak, M., Reiss, J., & Cooper, D. (1992) · Human Genetics · doi:10.1007/bf00210743 · Cited by 1,324
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Lewis, B. P., Green, R. E., & Brenner, S. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0136770100 · Cited by 1,067
Predictive Identification of Exonic Splicing Enhancers in Human Genes
Fairbrother, W. G., Yeh, R.-F., Sharp, P. A., & Burge, C. B. (2002) · Science · doi:10.1126/science.1073774 · Cited by 1,036
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Wu, J. Y., & Maniatis, T. (1993) · Cell · doi:10.1016/0092-8674(93)90316-i · Cited by 750
Aartsma‐Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. B., & Den Dunnen, J. T. (2006) · Muscle & Nerve · doi:10.1002/mus.20586 · Cited by 739
Self-citationCartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Exon definition may facilitate splice site selection in RNAs with multiple exons.
Robberson, B. L., Cote, G. J., & Berget, S. M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.1.84 · Cited by 725
Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction
Beggs, A., Koenig, M., Boyce, F., & Kunkel, L. (1990) · Human Genetics · doi:10.1007/bf00205170 · Cited by 688
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
MyD88, an Adapter Protein Involved in Interleukin-1 Signaling
Burns, K., Martinon, F., Esslinger, C., Pahl, H., Schneider, P., Bodmer, J.-L., Di Marco, F., French, L., & Tschopp, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12203 · Cited by 631
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×
“Dystrophin can be largely functional as long as the N- and C-terminal domains are present to convey the link between the cytoskeleton and the extracellular matrix (England et al. 1990; Mirabella et al. 1998).”
BackgroundMechanisms of disease: genetic causes of familial hypercholesterolemia
Soutar, A. K., & Naoumova, R. P. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0836 · Cited by 608
Scaffidi, P., & Misteli, T. (2005) · Nature Medicine · doi:10.1038/nm1204 · Cited by 553
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520
Smith, P. J., Zhang, C., Wang, J., Chew, S. L., Zhang, M. Q., & Krainer, A. R. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl171 · Cited by 515
Burns, K., Janssens, S., Brissoni, B., Olivos, N., Beyaert, R., & Tschopp, J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021790 · Cited by 512
Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Computational definition of sequence motifs governing constitutive exon splicing
Zhang, X. H.-F., & Chasin, L. A. (2004) · Genes & Development · doi:10.1101/gad.1195304 · Cited by 419
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
Lu, Q. L., Mann, C. J., Lou, F., Bou-Gharios, G., Morris, G. E., Xue, S.-A., Fletcher, S., Partridge, T. A., & Wilton, S. D. (2003) · Nature Medicine · doi:10.1038/nm897 · Cited by 398
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Freiburg, A., Trombitas, K., Hell, W., Cazorla, O., Fougerousse, F., Centner, T., Kolmerer, B., Witt, C., Beckmann, J. S., Gregorio, C. C., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.11.1114 · Cited by 386
Tacke, R., & Manley, J. L. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07360.x · Cited by 370
The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced
Tennyson, C. N., Klamut, H. J., & Worton, R. G. (1995) · Nature Genetics · doi:10.1038/ng0295-184 · Cited by 369
Ars, E. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.237 · Cited by 358
WT1 proteins: functions in growth and differentiation
Scharnhorst, V., van der Eb, A. J., & Jochemsen, A. G. (2001) · Gene · doi:10.1016/s0378-1119(01)00593-5 · Cited by 353
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
The connection between splicing and cancer
Srebrow, A., & Kornblihtt, A. R. (2006) · Journal of Cell Science · doi:10.1242/jcs.03053 · Cited by 335
Splicing Defects in the Ataxia-Telangiectasia Gene, ATM: Underlying Mutations and Consequences
Teraoka, S. N., Telatar, M., Becker-Catania, S., Liang, T., Önengüt, S., Tolun, A., Chessa, L., Sanal, Ö., Bernatowska, E., Gatti, R. A., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302418 · Cited by 316
Dystrophin–glycoprotein complex: Its role in the molecular pathogenesis of muscular dystrophies
Matsumura, K., & Campbell, K. P. (1994) · Muscle & Nerve · doi:10.1002/mus.880170103 · Cited by 311
Systemically delivered antisense oligomers upregulate gene expression in mouse tissues
Sazani, P., Gemignani, F., Kang, S.-H., Maier, M. A., Manoharan, M., Persmark, M., Bortner, D., & Kole, R. (2002) · Nature Biotechnology · doi:10.1038/nbt759 · Cited by 301
Correction of disease-associated exon skipping by synthetic exon-specific activators
Cartegni, L., & Krainer, A. R. (2003) · Nature Structural Biology · doi:10.1038/nsb887 · Cited by 301
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
Davis, M. I., Bennett, M. J., Thomas, L. M., & Bjorkman, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502101102 · Cited by 296
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
van Deutekom, J. C. T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.15.1547 · Cited by 293
Skordis, L. A., Dunckley, M. G., Yue, B., Eperon, I. C., & Muntoni, F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0633863100 · Cited by 274
Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C., & Dickson, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1083 · Cited by 255
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
Aartsma-Rus, A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg100 · Cited by 253
Self-citationEfficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., Miller, D. A., & Chamberlain, J. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.016 · Cited by 251
Varani, L., Hasegawa, M., Spillantini, M. G., Smith, M. J., Murrell, J. R., Ghetti, B., Klug, A., Goedert, M., & Varani, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8229 · Cited by 247
Lipid disorders and mutations in the APOB gene
Whitfield, A. J., Barrett, P. H. R., van Bockxmeer, F. M., & Burnett, J. R. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038026 · Cited by 243
International SMA consortium meeting
Munsat, T. L. (1992) · Medical Entomology and Zoology · Cited by 243
Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides
Sierakowska, H., Sambade, M. J., Agrawal, S., & Kole, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.12840 · Cited by 236
Advances in Duchenne muscular dystrophy gene therapy
van Deutekom, J. C. T., & van Ommen, G.-J. B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1180 · Cited by 221
Self-citationRibonuclease H. An Enzyme Degrading the RNA Moiety of DNA-RNA Hybrids
Hausen, P., & Stein, H. (1970) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1970.tb00287.x · Cited by 218
Wilton, S. D., Lloyd, F., Carville, K., Fletcher, S., Honeyman, K., Agrawal, S., & Kole, R. (1999) · Neuromuscular Disorders · doi:10.1016/s0960-8966(99)00010-3 · Cited by 217
Béroud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V., Monnier, N., Moizard, M.-P., Voelckel, M.-A., Calemard, L. M., Boisseau, P., et al. (2007) · Human Mutation · doi:10.1002/humu.20428 · Cited by 207
McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302800 · Cited by 207
Pathogenesis of rheumatoid arthritis
Harris, E. D. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90072-0 · Cited by 202
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
Self-citationMorpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle
Gebski, B. L., Mann, C. J., Fletcher, S., & Wilton, S. D. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg196 · Cited by 194
Single Nucleotide Polymorphism–Based Validation of Exonic Splicing Enhancers
Fairbrother, W. G., Holste, D., Burge, C. B., & Sharp, P. A. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020268 · Cited by 191
PATHOGENESIS OF RHEUMATOID ARTHRITIS
Panayi, G. S., Corrigall, V. M., & Pitzalis, C. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70204-0 · Cited by 189
Morita, K., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., & Koizumi, M. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00683-7 · Cited by 188
Fletcher, S., Honeyman, K., Fall, A. M., Harding, P. L., Johnsen, R. D., & Wilton, S. D. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.838 · Cited by 182
Su, S. L., Huang, I.-P., Fair, W. R., Powell, C. T., & Heston, W. D. W. (1995) · PubMed · Cited by 180
Improvement through novel chemical modifications
Kurreck, J. (2003) · Cited by 179
Mercatante, D. R., Mohler, J. L., & Kole, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209236200 · Cited by 174
First "Antisense" Drug Will Treat CMV Retinitis
Marwick, C. (1998) · JAMA · doi:10.1001/jama.280.10.871-jmn0909-6-1 · Cited by 167
Friedman, K. J., Kole, J., Cohn, J. A., Knowles, M. R., Silverman, L. M., & Kole, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36193 · Cited by 166
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
AMANTANA, A., & IVERSEN, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.07.001 · Cited by 163
The WT1 Wilms' tumor suppressor gene: How much do we really know?
Reddy, J. C., & Licht, J. D. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00014-7 · Cited by 162
Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations
Roberts, R. G., Gardner, R. J., & Bobrow, M. (1994) · Human Mutation · doi:10.1002/humu.1380040102 · Cited by 162
White, S. J., Aartsma-Rus, A. M., Flanigan, K. M., Weiss, R. B., Kneppers, A. L. J., Lalic, T., Janson, A. A. M., Ginjaar, H. B., Breuning, M. H., & den Dunnen, J. T. (2006) · Human Mutation · doi:10.1002/humu.20367 · Cited by 161
Self-citationFluiter, K. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg185 · Cited by 158
Morpholino Oligomer–Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse
Fletcher, S., Honeyman, K., Fall, A. M., Harding, P. L., Johnsen, R. D., Steinhaus, J. P., Moulton, H. M., Iversen, P. L., & Wilton, S. D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300245 · Cited by 158
Matsuo, M., Masumura, T., Nishio, H., Nakajima, T., Kitoh, Y., Takumi, T., Koga, J., & Nakamura, H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115244 · Cited by 153
Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript
Wilton, S. D., Fall, A., Harding, P. L., McClorey, G., Coleman, C., & Fletcher, S. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300095 · Cited by 153
Shiga, N., Takeshima, Y., Sakamoto, H., Inoue, K., Yokota, Y., Yokoyama, M., & Matsuo, M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119757 · Cited by 152
Wimmer, K., Roca, X., Beiglböck, H., Callens, T., Etzler, J., Rao, A. R., Krainer, A. R., Fonatsch, C., & Messiaen, L. M. (2007) · Human Mutation · doi:10.1002/humu.20493 · Cited by 147
Mann, C. J., Honeyman, K., McClorey, G., Fletcher, S., & Wilton, S. D. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.295 · Cited by 140
Pramono, Z. A. D., Takeshima, Y., Alimsardjono, H., Ishii, A., Takeda, S., & Matsuo, M. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1375 · Cited by 139
Deburgrave, N., Daoud, F., Llense, S., Kaplan, J., Récan, D., Peccate, C., Burghes, A. H. M., Béroud, C., García, L., Kaplan, J., et al. (2006) · Human Mutation · doi:10.1002/humu.20422 · Cited by 127
Aartsma-Rus, A. M., Kaman, W. E., Bremmer-Bout, M., Janson, A. A. M., den Dunnen, J. T., van Ommen, G. B., & van Deutekom, J. C. T. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302313 · Cited by 126
Self-citationSynchronous selection of homing peptides for multiple tissues byin vivophage display
Kolonin, M. G., Sun, J. D., Do, K.-A., Vidal, C. I., Ji, Y., Baggerly, K., Pasqualini, R., Amp, W., Kolonin, M. G., Sun, J. D., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5186fje · Cited by 124
Kalbfuss, B., Mabon, S. A., & Misteli, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105113200 · Cited by 116
Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H., & Matsuo, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117693 · Cited by 114
Efficient and Persistent Splice Switching by Systemically Delivered LNA Oligonucleotides in Mice
Roberts, J., Palma, E., Sazani, P., Ørum, H., Cho, M., & Kole, R. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.017 · Cited by 114
Aartsma-Rus, A. M., de Winter, C. L., Janson, A. A. M., Kaman, W. E., van Ommen, G. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2005) · Oligonucleotides · doi:10.1089/oli.2005.15.284 · Cited by 111
Self-citationDisset, A., Bourgeois, C. F., Benmalek, N., Claustres, M., Stévenin, J., & Tuffery‐Giraud, S. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl015 · Cited by 109
RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA
Chester, A., Scott, J., Anant, S., & Navaratnam, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00219-0 · Cited by 101
Ginjaar, I. B., Kneppers, A. L. J., Meulen, J.-D. M. V. D., Anderson, L. V. B., Bremmer-Bout, M., van Deutekom, J. C., Weegenaar, J., den Dunnen, J. T., & Bakker, E. (2000) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200535 · Cited by 92
Aartsma-Rus, A. M., Kaman, W. E., Weij, R., den Dunnen, J. T., van Ommen, G. B., & van Deutekom, J. C. T. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.022 · Cited by 91
Self-citationMolecular deletion patterns in Duchenne and Becker type muscular dystrophy
Liechti‐Gallati, S., Koenig, M., Kunkel, L. M., Frey, D., Boltshauser, E., Schneider, V., Braga, S., & Moser, H. R. (1989) · Human Genetics · doi:10.1007/bf00283688 · Cited by 86
Goto, M., Sawamura, D., Nishie, W., Sakai, K., McMillan, J. R., Akiyama, M., & Shimizu, H. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700435 · Cited by 85
McGrath, J. A., Ashton, G. H. S., Mellerio, J. E., McMillan, J. R., Eady, R. A. J., Salas-Alanis, J. C., & Swensson, O. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00709.x · Cited by 85
Marquis, J., Meyer, K., Angehrn, L., Kämpfer, S. S., Rothen‐Rutishauser, B., & Schümperli, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300200 · Cited by 82
The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping
Harding, P. L., Fall, A., Honeyman, K., Fletcher, S., & Wilton, S. D. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300006 · Cited by 82
Cytokines or Their Antagonists for the Treatment of Asthma
O’Byrne, P. M. (2006) · CHEST Journal · doi:10.1378/chest.130.1.244 · Cited by 80
Takeshima, Y., Wada, H., Yagi, M., et al. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00326-6 · Cited by 80
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
Aartsma-Rus, A. M., Janson, A. A. M., van Ommen, G. B., & van Deutekom, J. C. T. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-43 · Cited by 77
Self-citationKarras, J. G., Maier, M. A., Lü, T., Watt, A. T., & Manoharan, M. (2001) · Biochemistry · doi:10.1021/bi010263l · Cited by 70
Induced dystrophin exon skipping in human muscle explants
McClorey, G., Fall, A., Moulton, H. M., Iversen, P. L., Rasko, J. E. J., Ryan, M. M., Fletcher, S., & Wilton, S. D. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.05.017 · Cited by 66
Schwarze, U., Starman, B. J., & Byers, P. H. (1999) · The American Journal of Human Genetics · doi:10.1086/302512 · Cited by 64
The role of SMN in spinal muscular atrophy
Jablonka, S., Rossoll, W., Schrank, B., & Sendtner, M. (2000) · Journal of Neurology · doi:10.1007/s004150050555 · Cited by 62
Suter, D., Tomasini, R., Reber, U., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.13.2415 · Cited by 55
Vickers, T. A., Zhang, H., Graham, M. J., Lemonidis, K. M., Zhao, C., & Dean, N. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3652 · Cited by 54
Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A
Liu, S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh715 · Cited by 54
Mercatante, D. R., Sazani, P., & Kole, R. (2001) · Current Cancer Drug Targets · doi:10.2174/1568009013334124 · Cited by 52
A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene
Matsuo, M., Masumura, T., Nakajima, T., Kitoh, Y., Takumi, T., Nishio, H., Koga, J., & Nakamura, H. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)92185-3 · Cited by 52
Khoo, B. C. E., Roca, X., Chew, S. L., & Krainer, A. R. (2007) · BMC Molecular Biology · doi:10.1186/1471-2199-8-3 · Cited by 46
Tuffery‐Giraud, S., Saquet, C., Chambert, S., Échenne, B., Cuisset, J., Rivier, F., Cossée, M., Philippe, C., Monnier, N., Bieth, É., et al. (2004) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.05.002 · Cited by 44
Aartsma-Rus, A. M., JANSON, A. A. M., Heemskerk, J., de Winter, C. L., van Ommen, G. B., & van Deutekom, J. C. T. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.058 · Cited by 41
Self-citationInduction of revertant fibres in the mdx mouse using antisense oligonucleotides
Fall, A., Johnsen, R. D., Honeyman, K., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-4-3 · Cited by 38
Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy
Massimiliano Mirabella, A., Galluzzi, G., Manfredi, G., Bertini, E., Ricci, E., Leo, R. D., Tonali, P. A., & Servidei, S. (1998) · Neurology · doi:10.1212/wnl.51.2.592 · Cited by 37
Inhibition of HIV‐1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping
Asparuhova, M. B., Marti, G., Liu, S., Serhan, F., Trono, D., & Schümperli, D. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1027 · Cited by 33
Ghosh, D., & Barry, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.21.13667-13672.2005 · Cited by 31
Analysis of Prostate-Specific Membrane Antigen Splice Variants in LNCap Cells
Williams, T., & Kole, R. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.186 · Cited by 26
Cited by
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Gene regulation by antisense transcription
Pelechano, V., & Steinmetz, L. M. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3594 · Cited by 634
Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Self-citationAlternative splicing and disease
Tazi, J., Bakkour, N., & Stamm, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.017 · Cited by 540
Metadata
- Authors
- Aartsma-Rus, A., & van Ommen, G.-J. B.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2007-08-07
- Volume
- 13
- Issue
- 10
- Pages
- 1609-1624
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2149543855
- Cited by
- 267
- References
- 124
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.